Short answer
Vaxcyte, Inc. (PCVX) filed an 8-K current report with the SEC on June 23, 2026 reporting Item 5.02 (Departure/Election of Directors or Officers). Jacks Lee retired from the Board June 17, 2026, without disagreement, but remains involved as a strategic supply and manufacturing consultant.
Vaxcyte, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 5.02 · Departure/Election of Directors or Officers
- Jacks Lee retired from the Board June 17, 2026, without disagreement, but remains involved as a strategic supply and manufacturing consultant
- Moncef Slaoui appointed independent Class II director through the 2028 annual meeting
- Slaoui’s industry experience may strengthen oversight of global vaccine supply and manufacturing operations
- Annual equity grant value for directors currently set at $430,000, plus standard indemnification agreement
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Vaxcyte, Inc. 8-K filings
Get the next PCVX 8-K as it lands
Follow PCVX for push alerts, or ask the research agent what this filing means.